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carcinoma. 8.7% underwent radical surgery, 23.7% received chemo-
therapy only, 21.6% radiotherapy against the tumour (thereof stereotac-
tic 5,1%), and 1,5% concomitant chemo-radiotherapy. 6,3% received 
radiotherapy against metastases, and 38% had no therapy. Only 6.3% 
were given second-line chemotherapy. Survival was 219 and 190 days 
for patients 75-80 years and >80 years, respectively. Patients with PS=0 
survived 533 days, those with PS=4 only 20 days. Survival among 
smoker or former smokers and never smokers were 212 and 132 days, 
respectively. Survival among those who received chemotherapy was 
573 days, while for the others it was 181 days.
Conclusions: Signiﬁcant survival among patients given second line 
chemotherapy (p<0.036). Signiﬁcant survival among patients between 
75-80 versus > 80 years old (P<0.032). Treatment of elderly patients 
with lung cancer is feasible if they have a good PS and seems to result 
in prolonged survival.
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Background: Pemetrexed is a standard treatment for patients with 
locally advanced or metastatic NSCLC who had prior chemotherapy. In 
an international phase III study comparing pemetrexed with docetaxel 
in pretreated patients with NSCLC, pemetrexed showed clinically 
similar efﬁcacy to docetaxel with median survival time (MST) of 8.3 
months. In our Japanese randomized phase II study, the treatment with 
either pemetrexed 500 mg/m2 (Pem 500) and 1000 mg/m2 (Pem 1000) 
showed favorable response rates of 18.5% and 14.8%, respectively. We 
report survival and quality of life (QOL) results of the Japanese phase 
II study.
Methods: Patients with PS 0-2, measurable, stage III/IV NSCLC, who 
had previously received 1 or 2 chemotherapy regimens, were random-
ized to receive either Pem 500 or Pem 1000 on day 1 of a 21-day 
schedule. The primary endpoint was response rate, which has already 
been reported. The secondary endpoints included overall survival and 
QOL. Overall survival was calculated with a Kaplan-Meier method. 
The QOL scores of FACT-L LCS questionnaire were measured at base-
line, before the 2nd and 3rd cycle, and also at 3 months after the regis-
tration to the ﬁrst cycle. Changes from the baseline were calculated.
Results: From October 2004 to October 2005, 244 pts were enrolled at 
28 centers, 226 patients were randomized and treated, and 216 patients 
were evaluated for efﬁcacy. Baseline patient characteristics (Pem 
500/Pem 1000: 108/108 pts) were well balanced between the two arms: 
Males 63%/64%; median age 62/62 years (range: 37-74/26-74); PS 0-1 
94%/94%; stage IV 81%/78%. The median number of treatment cycles 
completed on both arms was 3 (range 1-20+ for Pem 500 and 1-14+ 
for Pem 1000). One year survival rates were 59.2% for Pem 500, and 
53.7% for Pem 1000 with MST of 15.7 and 12.6 months, respectively. 
The QOL scores of LCS questionnaire were obtained from 107/107 
patients (Pem 500/Pem 1000) at baseline, 101/98 patients before the 
2nd cycle, 84/72 patients before the 3rd cycle, and 59/61 patients at the 
last time point (Pem 500/Pem 1000). In both arms, the total LCS scores 
were well sustained from the baseline without aggravation among the 
patients who completed the questionnaire at the last time point. De-
tailed QOL results will be reported at the presentation. 
Conclusions: Pemetrexed is an active agent for pretreated patients with 
NSCLC. Pem 500 showed numerically better response rate and survival 
than Pem 1000. Based on this study, the use of Pem 500 is recommend-
ed for pts with NSCLC in a 2nd or 3rd line setting.
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Background: Doc has clear-cut therapeutic superiority compared to 
best supportive care or ifosfamide/vinorelbine and, as a result, is the 
standard of comparison in the second line setting. In the pre-peme-
trexed era, Gem, in phase II studies, also demonstrated activity in the 
salvage setting with favorable response and survival rates. We therefore 
mounted a phase II trial pairing these two agents in pts with progressive 
disease after prior platinum-based therapy.
Materials and Methods: Pts with advanced NSCLC and ECOG PS 
0-1 progressing either during or after prior platinum-based therapy 
received Doc 40 mg/m2 days 1 and 8, in combination with Gem 800 
mg/m2 days 1 and 8. In the absence of dose limiting myelosuppression 
or other gr ≥3 toxicities, Gem dose was escalated on an intra-patient 
basis to 1000 mg/m2 days 1 and 8. Pts continued treatment until disease 
progression or unacceptable toxicity.
Results: 35 pts were enrolled: 20 (57%) were male; 69 % were ECOG 
PS 1; 57% had received prior XRT. Median age was 61 (range 30-79). 
Median time from initial diagnosis to enrollment was 12.4 mos. 170 
cycles total were administered (median 4, range 1-16). 35% received 
≥ 6 cycles. Overall response rate was 24% (95% CI 12-39%). Median 
event free survival (EFS) was 5.7 mos; median overall survival 12.5 
mos. 1 year survival rate was 51%, and 2 year survival rate 20%. Those 
enrolled within 12 mos of initial diagnosis had poorer EFS compared 
to those after 12 mos (log rank p=0.04). There were no treatment-re-
lated deaths. Typical grade ≥ 3 toxicities included neutropenia (58%), 
diarrhea (6%), pneumonitis (9%), and dermatitis (9%), including nail 
changes.
Conclusion: Combination docetaxel and gemcitabine administered 
on a weekly basis, days 1 and 8 every 3 weeks in good performance 
NSCLC patients with PD after/during platinum-based therapy appears 
encouraging, and presents a viable option in this population. Proof of 
beneﬁt requires phase III testing. 
